Insiders who have reported open-market trades at the same companies as BROADWOOD PARTNERS, L.P.. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
BROADWOOD PARTNERS, L.P. is an investment firm, tracked as 10% Owner of Insight Molecular Diagnostics Inc. (IMDX). InsiderAlpha holds 12 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did BROADWOOD PARTNERS, L.P. last file a Form 4?
The most recent primary Form 4 on record is dated 27 April 2026, one of 12 filings going back to 2024.
Has BROADWOOD PARTNERS, L.P. been buying or selling stock?
Recorded transactions: 68 open-market purchases ($91.70M) and 0 open-market sales across all tracked filings.
BROADWOOD PARTNERS, L.P. is 10% Owner of Insight Molecular Diagnostics Inc. (IMDX). 12 SEC Form 4 filings on record going back to 2024, most recently on 27 April 2026. Most recent open-market trade: bought $913K of IMDX on 27 April 2026. Lifetime open-market purchases: $91.70M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by BROADWOOD PARTNERS, L.P..
InsiderAlpha's records for BROADWOOD PARTNERS, L.P. go back to 2024: 12 primary Form 4 filings, an average of 4.0 per year. The typical open-market purchase is $2.70M (34 of 68 buys carry a usable dollar value, totaling $91.70M). The largest single buy on record is $22.22M of STAA in 2025. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
